Increased Levels of Runt-Related Transcription Factor 2 Are Associated With Poor Survival of Patients With Idiopathic Pulmonary Arterial Hypertension

Overview

Journal Am J Mens Health

Specialties Health Services
Public Health

Date 2020 Jul 28

PMID 32715877

Citations 3

Authors

Xuntao Yuan

Zuogang Wang

Lan Wang

Qinhua Zhao

Sugang Gong

Yuanyuan Sun

Qian Liu

Ping Yuan

Affiliations

Soon will be listed here.

Abstract

Runt-related transcription factor 2 (RUNX2) plays a pivotal role in the pathogenesis of pulmonary arterial hypertension (PAH); yet, whether circulating levels of RUNX2 can predict survival of patients with idiopathic PAH (IPAH) is still unclear. The present study aimed to investigate the correlation between circulating levels of RUNX2 and survival of patients with IPAH. Blood samples were collected from 46 incident patients with IPAH and 30 healthy controls in Shanghai Pulmonary Hospital. Levels of RUNX2 were measured using ELISA. Linear regression and cox proportional hazards analysis were performed to assess the prognostic value of RUNX2 levels in predicting survival using the Kaplan-Meier method. Nonsurvivors had significantly shorter 6MWD, higher levels of NT-proBNP, increased mRAP, mPAP, mPAWP, PVR, and decreased CO as well as CI, compared with survivors ( < .05). Plasma levels of RUNX2 were significantly higher in nonsurvival and survival patients with IPAH compared with controls ( ≤ .001), and higher in nonsurvivors than in survivors ( = .001). RUNX2 levels served as an independent predictor of survival in these patients ( < .001). RUNX2 levels ≥41.5 ng/ml had a sensitivity of 80.0% and a specificity of 74.2% by ROC analysis. Patients with a RUNX2 level <41.5 ng/ml and/or mRAP <3.5 mmHg had a significantly better prognosis than those with a higher RUNX2 level in all subjects as well as in male or female patients ( < .05). The level of circulating RUNX2 is an independent predictor for survival and it is correlated with the clinical severity of IPAH.

Citing Articles

The role of miR-433-3p in vascular calcification in type 2 diabetic patients: targeting WNT/β-Catenin and RANKL/RANK/OPG signaling pathways.

Elshamy A, Hafez Y, Safa M, Ibrahim H, Khalfallah M, Rizk F Mol Biol Rep. 2023; 50(11):9073-9083.

PMID: 37728820 PMC: 10635945. DOI: 10.1007/s11033-023-08792-9.

Prognostic value and immune characteristics of RUNX gene family in human cancers: a pan-cancer analysis.

Zhao H, Chen Y, Shen P, Gong L Aging (Albany NY). 2022; 14(9):4014-4035.

PMID: 35522574 PMC: 9134966. DOI: 10.18632/aging.204065.

Impact of Parthanatos on the Increased Risk of Onset and Mortality in Male Patients With Pulmonary Hypertension.

Lv Z, Li F, Wang L, Zhao Q, Gang G, Wu Y Am J Mens Health. 2021; 15(3):15579883211029458.

PMID: 34190625 PMC: 8256257. DOI: 10.1177/15579883211029458.

References

Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N . Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999; 160(2):487-92. DOI: 10.1164/ajrccm.160.2.9812078. View

Benza R, Miller D, Barst R, Badesch D, Frost A, McGoon M . An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448-456. DOI: 10.1378/chest.11-1460. View

Jing Z, Xu X, Han Z, Wu Y, Deng K, Wang H . Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007; 132(2):373-9. DOI: 10.1378/chest.06-2913. View

Zhang Y, Wang L, Lu W, Yuan P, Wu W, Zhou Y . Association Between High FSH, Low Progesterone, and Idiopathic Pulmonary Arterial Hypertension in Women of Reproductive Age. Am J Hypertens. 2019; 33(1):99-105. DOI: 10.1093/ajh/hpz143. View

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023-30. DOI: 10.1164/rccm.200510-1668OC. View

Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z . The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med. 2011; 3(88):88ra55. PMC: 3744110. DOI: 10.1126/scitranslmed.3002194. View

Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M . Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. 2003; 108(7):844-8. DOI: 10.1161/01.CIR.0000084544.54513.E2. View

Federici C, Drake K, Rigelsky C, McNelly L, Meade S, Comhair S . Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015; 192(2):219-28. PMC: 4532823. DOI: 10.1164/rccm.201411-2128OC. View

Courboulin A, Paulin R, Giguere N, Saksouk N, Perreault T, Meloche J . Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011; 208(3):535-48. PMC: 3058572. DOI: 10.1084/jem.20101812. View

10.

Wysokinski D, Blasiak J, Pawlowska E . Role of RUNX2 in Breast Carcinogenesis. Int J Mol Sci. 2015; 16(9):20969-93. PMC: 4613236. DOI: 10.3390/ijms160920969. View

11.

Ruffenach G, Chabot S, Tanguay V, Courboulin A, Boucherat O, Potus F . Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2016; 194(10):1273-1285. DOI: 10.1164/rccm.201512-2380OC. View

12.

Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S . Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2013; 129(7):786-97. DOI: 10.1161/CIRCULATIONAHA.113.006167. View

13.

Galie N, Corris P, Frost A, Girgis R, Granton J, Jing Z . Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D60-72. DOI: 10.1016/j.jacc.2013.10.031. View

14.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

15.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

16.

Al-Naamani N, Palevsky H, Lederer D, Horn E, Mathai S, Roberts K . Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2015; 13(1):25-30. PMC: 4722842. DOI: 10.1513/AnnalsATS.201508-543OC. View

17.

Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J . Calcification of medial elastic fibers and aortic elasticity. Hypertension. 1997; 29(4):999-1006. DOI: 10.1161/01.hyp.29.4.999. View

18.

Manes A, Palazzini M, Leci E, Bacchi Reggiani M, Branzi A, Galie N . Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2013; 35(11):716-24. DOI: 10.1093/eurheartj/eht072. View

19.

Vlachopoulos C, Aznaouridis K, Stefanadis C . Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55(13):1318-27. DOI: 10.1016/j.jacc.2009.10.061. View

20.

Komori T . Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 2009; 339(1):189-95. DOI: 10.1007/s00441-009-0832-8. View